Background. As we emerge into the genomic medicine era, the epidemiology of diseases is taken for granted. Accurate prevalence figures, especially of rare diseases (RDs, ≤50/ 100 000), will become even more important for purposes of health care and societal planning. We noticed that the numbers of affected individuals in regionally established registries for mainly hereditary RDs do not align with published estimated and expected prevalence figures. We therefore hypothesized that such non-population-based means overestimate RDs and sought to address this by recalculating prevalence for an important 'common' hereditary disease, autosomal-dominant polycystic kidney disease (ADPKD) whereby presumed-prevalence is 100-250/100 000 Methods. The Else-Kroener-Fresenius-ADPKD-Study in south-west Germany with a population of 2 727 351 inhabitants was established with the cooperation of all nephrology centres. Furthermore, general practitioners, internists, urologists, human geneticists and neurosurgery centres were contacted with questionnaires for demographic, family and kidney function data. Germline-mutation screening of susceptibility genes PKD1 and PKD2 was offered. Official population data for 2010 were used for overall and kidney function-adjusted prevalence estimations. Results. A total of 891 subjects, 658 index-cases and 233 relatives, aged 10-89 (mean 52), were registered, with >90% response rate, 398 by nephrologists and 493 by non-nephrologists. Molecular-genetic analyses contributed to confirmation of the diagnosis in 57%. The overall prevalence of ADPKD was 32.7/100 000 reaching a maximum of 57.3/100 000 in the 6th decade of life. Conclusions. Prevalence of ADPKD is overestimated by 2-to 5-fold and close to the limit of RDs which may be of broad clinical, logistic and policy implications.
I N T RO D U C T I O N
A rare disease (RD) is operationally defined as one occurring in 50 or fewer patients in a population of 100 000. The National Organization for RDs (http://www.rarediseases.org/) lists more than 7000 entities, and more than 30 million Americans are affected. RDs tend to have a high genetic load and are usually caused by Mendelian gene mutations which are often actionable when identified. They have also recently proven to be effective demonstration populations for molecular-targeted therapies [1] . RDs have thus attracted recognition, and centres for RDs have been founded worldwide. In Germany, 4 million of the 80 million population are estimated to have RDs (http ://www.namse.de/).
In the era of genomic medicine and personalizing health care, prevalence figures and population-based registries grow in importance. In theory, therefore, population-based prevalence estimates of an RD, for example, should be a figure close to the accepted published figure. However, we have noticed that the number of population-based registrants is below the expected, if indeed the existing prevalence estimates are correct. Because 70% of RDs have a hereditary origin, with accompanying prevalence figures (http://www.orpha.net/consor/ cgi-bin/index.php), we sought to address this inconsistency in prevalence figures by re-examining a well-known hereditary disorder, autosomal-dominant polycystic kidney disease (ADPKD). The prevalence figure for ADPKD of 100-250:100 000 inhabitants dates back to 1983 [2] , and is still believed to be accurate and remains continuously cited in an overwhelming majority of the 100 most recently published scientific papers on this topic found via a PubMed search. We therefore selected ADPKD as a demonstration disease to determine whether this highly accepted prevalence figure was an overestimate and to delineate the reasons for over-or underestimation of disease prevalence.
ADPKD (OMIM#173900) is accepted as being among the most common inherited disorders in humans. Dominant features are bilateral enlarged polycystic kidneys and progressive impairment of renal function. Most patients with ADPKD need renal replacement therapy in their fifth to sixth decade of life [3] . Extrarenal manifestations such as multiple liver cysts occur in 60-90% and intracranial aneurysms in 5-10% of the patients [3] [4] [5] . ADPKD is a leading cause for renal replacement therapy comprising 5-10% of all patients with end-stage renal failure [6] [7] [8] . Currently, treatment is reactive, focused on complications and aims towards blood pressure control, recognition of urinary tract infections and vascular protection. It is, however, expected that new therapeutic options will have a potent effect on formation and growth of renal cysts and achieve attenuation of loss of renal function. Thus, the poor prognosis may be considerably ameliorated [9, 10] . However, available data for candidate molecular-targeted therapies have so far not opened new approved treatment options [11] [12] [13] [14] . ADPKD is genetically heterogeneous and caused by germline mutations of the susceptibility genes PKD1 and PKD2. PKD2 mutation-positive patients experience end-stage renal failure about 2 decades later than PKD1 mutation carriers [3, 15] .
In the context of identification of individuals-at-risk, screening and intervention, e.g. with expectant treatment
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options, it is important to elucidate the true prevalence of ADPKD patients. Therefore, in order to address our hypothesis, we sought to re-analyse the population-based prevalence of ADPKD using a geographically well-characterized region.
M AT E R I A L S A N D M E T H O D S
The catchment area The Else-Kroener-Fresenius-Registry of ADPKD in Germany (EKFS-ADPKD-Registry) was established in 2004 at the University Medical Center of Freiburg, Germany. The population-based registry covers a circumscribed area in south-west Germany with 11 administrative counties and a population of 2 727 351 inhabitants ( Figure 1 and Table 1 ).
Recruitment of patients
The registration procedure was performed prospectively. For this reason, a study nurse was tasked with data collection. Each registrant had a personal interview for demographic and clinical data including detailed family history. The study nurse had regular contact with all centres of nephrology which included the hospitals of Karlsruhe and Baden-Baden and 20 other centres organized as private entities for nephrology and dialysis ( Figure 1) .
In 2009, all centres were asked to review whether all patients had been registered. Subsequently, we considered a potential registration failure and decided to systematically contact, in parallel, non-nephrologists in our area. All registered internists, general practitioners, urologists and medical geneticists were asked to register their ADPKD patients. The questionnaire included such questions as: if patients with abdominal complaints or elevated serum creatinine were generally explored with ultrasonography of the abdomen and if patients with hypertension had measurements of serum creatinine. We also checked all patients with cerebral aneurysms seen at the two departments of neurosurgery in the catchment area if ADPKD was the underlying disorder. Finally, we considered whether patients with end-stage renal failure received dialysis care in centres adjacent to, but outside, the catchment area by contacting all neighbouring nephrology centres.
Inclusion criteria Diagnosis of ADPKD followed the internationally approved standard criteria and included clinical findings and family history [16] .
Excluded were PKD patients with autosomal-recessive PKD (n = 2), autosomal medullary cystic kidney disease (n = 2), nephronophthisis (n = 5), tuberous sclerosis complex (n = 3) and von Hippel-Lindau disease (n = 4). Also excluded were patients with constitutional abnormalities like orofacial dysplasia (n = 1) [3] and patients with aquired cystic kidney disease.
Registration of data
For each registrant, a set of nine core pieces of information were obtained, namely initials, age, gender, race, status of renal function (serum creatinine, dialysis, transplantation), presence of liver cysts, hypertension, a family history for ADPKD and the 5-digit ZIP code of the place of residence. In order to underscore the importance of this project, all questionnaires were sent out by mail hand-signed by the principal investigator. Renal insufficiency was assessed by glomerular filtration rate (eGFR) calculated by the CKD-EPI equation [17] 
Optimizing registration
In order to optimize registration, we asked each registrant to inform affected relatives to contact our study centre and registered them accordingly. Six thousand re-inquiries were sent out during 2010 in order to obtain the full data set of all registrants. It became apparent that this intense protocol was necessary to achieve a nearly complete registration. Finally, all participating physicians were approached with the key registration data of their patients in order to confirm accuracy. Optimizing of registration was adjusted to the data of the State Statistics Office of the State of Baden-Württemberg from 31 December 2010.
Molecular genetic studies
All registrants were offered genetic screening for germline mutations of the PKD1 and PKD2 genes which was performed as reported by us and others [18] [19] [20] [21] . We compared all identified germline variants to those listed at http://pkdb.mayo.edu/ cgi-bin/mutations.cgi. We used in silico analysis for detected missense variants for potential pathogenity by the programs SIFT, PolyPhen, SNAP and Mutation Taster [22] [23] [24] [25] and checked, if the sequences containing the variant were highly conserved by http://www.ensembl.org (Table 2) .
Prevalence estimation
We calculated the prevalence as number of registered cases/ number general population per age group as of 31 December 2010, the last official population registration report for the catchment area. Only living registered patients at that date were accounted for prevalence estimation. Population data for the catchment area were provided by the Baden-Württemberg State Office for Statistics (Statistisches Landesamt Baden-Württem-berg correct). This included the total of inhabitants of all counties as well as the specification in decades of life (Table 1) .
Consent
This epidemiological study was affirmatively reviewed by the Ethical Committee of the University Medical Center of Freiburg. For molecular genetic analyses of the susceptibility genes, all research participants provided written consent. This procedure was executed in contact with the ethics committee and according to the bylaws of the medical association of the German state of Baden-Württemberg and the administrator for data protection of the University of Freiburg.
R E S U LT S

Description of the catchment area
The south-western Germany catchment area, which is serviced by 23 nephrology centres, has a total population of 2 727 351 inhabitants. The structure of the population in the 11 counties is shown in Table 1 . This area has geographically and politically well-defined borders (Figure 1 ). The triangular region borders France to the west and Switzerland to the south. These borders are also administrative limits for insurance purposes. To the east, the narrow valleys and mountains of the Black Forest with marked decreasing population density are characteristic. Thus, the vast majority of the study population lives on the right bank of the Rhine valley around Basel down to Karlsruhe. A potential overlap of registered patients in the catchment area was checked against the neighbouring nephrology centres, but only five patients were identified and deleted.
Registration process and data collection process Until 2009, the nephrology centres registered a total of 392 individuals. After contacting 710 internists, 1351 private practitioners, 102 urologists and 12 human geneticists, the number of registrants increased to a total of 891. The response rate of the non-nephrologists to the first request was 48%. Questionnaires were sent out again to the 1200 non-responding clinicians. Thus, after second, third and fourth requests, responses 
O R I G I N A L A R T I C L E S
O R I G I N A L A R T I C L E SO R I G I N A L A R T I C L E SO R I G I N A L A R T I C L E S
O R I G I N A L A R T I C L E S A D P K D e p i d e m i o l o g y
were 64%, 83% and finally >90%, respectively. Finally, all core information was documented completely for 883 (99.1%) registrants.
Core demographic and clinical information of the registrants
The EKFS-ADPKD-Registry comprised 891 registrants, 416 males and 475 females, representing residents of southwest Germany in the 11 administrative counties shown in Table 1 . Age ranged from 10 to 89 (mean 52) years. All registrants were Caucasian. The 891 registrants included 658 nonrelated index cases and 233 relatives. Of note, 50% of the 658 index cases were registered by non-nephrologists. A family history for ADPKD was present in 469 of 658 (72%) index cases while 189 of 658 index cases had no known affected relatives. Stage 1 to Stage 5 chronic renal failure was present in 18.5, 21.5, 18.3, 6.8 and 34.9% (Table 3 ). Most with Stage 5 failure (283 of 305 registrants, 93%) were on dialysis or have transplanted kidneys. Multiple liver cysts were prevalent in 442, and cerebral aneurysms in 24 registrants.
Molecular genetic analyses
A total of 215 registrants were found to have germline mutations in PKD1 or PKD2. Mutations of PKD1 were identified in 145 and PKD2 in 34 unrelated index cases (Tables 4 and  5 ). Repeat mutations were observed for 14 different PKD1 mutations which were found in a total of 33 index cases (Table 4 ) and 7 different PKD2 mutations in a total of 17 index cases ( Table 5 ). The 126 different PKD1 mutations included 39 missense and 87 truncating mutations. The 24 different PKD2 mutations included 8 missense and 16 truncating mutations. We were not able to identify a mutation in 98 index cases.
Prevalence of ADPKD
The data of the general population in the studied area including the age distribution of the registered cases are shown in Table 1 . The overall prevalence of ADPKD was 32.5 per 100 000 residents. The prevalence differed considerably between the decades and reached a maximum of 57.3 per 100 000 in the sixth decade (Table 1) . Seemingly high prevalence of disease, e. g. >70 registrants per 100 000 inhabitants, were found in regions where affected relatives of index patients congregated.
D I S C U S S I O N
It is well accepted and demonstrated that individuals with RDs are best served, with proven best practices and best outcomes, in multidisciplinary centres of excellence for the RDs in question. It may be suggested that regions with such multidisciplinary centres for RDs may over-estimate prevalence figures. Paradoxically, where there are founder mutations for von Hippel-Lindau disease in south-west Germany, 658 patients are registered among 80 million total population (0.8/100 000, Neumann et al., unpublished data for the von Hippel-Lindau Registry for Germany). If we excluded the founder effect in the Black Forest area, only 473 (or 0.6/100 000) are registered with von Hippel-Lindau, instead of the predicted 3.2/100 000 [26] . 
Continued
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H.P.H. Neumann et al. Despite the presence of a founder mutation, this illustrates another example of over-estimation of prevalence, perhaps because of non-population-based (e.g. tertiary referral-based) estimates compared with the von Hippel-Lindau Registry, which is population based with high ascertainment. Our current population-based overall prevalence estimate for ADPKD is 32.7/100 000. It is important to note that agerelated prevalence is germane to this disease, ranging from 17.3/100 000 in the third decade to a high of 57.3/100 000 in the sixth decade. These figures are the result of an in-depth accurately and systematically established registry for a large and demographically well-characterized population in Germany. During this process and in examining how prevalence figures are estimated over time and space, we have realized a number of general challenges. This is a representative and large, welldefined catchment area which holds detailed recently updated structure of the general population with a very low estimated non-registration rate. We were able to interrogate and ascertain potential registrants from the broad spectrum of clinical specialities-only 50% of the cases with this classical kidney disease were registered by nephrologists. Although we had to perform four mail outs with 6000 inquiries, we did attain a response rate of >90% and a completion rate of >98% to the core questions. Despite these intensive efforts as evidenced also by successful accrual of high number of registrants who are asymptomatic index cases (Table 3) , it remained impossible to solve the problem of age-related penetrance for the first three decades of life. Many suspect that busy health care providers, especially from non-academic centres, who do not have time to contribute to clinical research, cite privacy regulations. The number of potential research participants, however, who are lost in this manner, is not easily estimated.
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From 1983 through 2001, studies from Britain, France, Portugal, Japan and the Seychelles on the prevalence of ADPKD have been published [27] [28] [29] [30] [31] . However, we believe that these studies were challenged by many of the issues relevant to epidemiologic studies. For example, they are likely based on small populations and/or incomplete and/or biased ascertainment. For instance, the study for the Seycelles was performed in a population of only 75 000 inhabitants [22] . Similarly, the studies from and for Japan, Wales and St. Brieuc/France did in part not comprise consented research participants who underwent comprehensive clinical survey; instead, they counted the affectation status by assuming 50% affected relatives in the [18, 20, 21] . In particular, the continuously most frequently cited study dates from 1983, from Olmsted County, Minnesota, with a population of only 86 000 inhabitants and based on patients on dialysis only including their pedigrees with a disorder estimation of 50% in first and 25% in second degree relatives [2, 3] . We have to realize that currently nobody will be able to define the true prevalence of ADPKD, since complete population screening, for example by renal ultrasonography, is impossible for practical and privacy reasons. Since ADPKD becomes symptomatic in the vast majority of the patients and since ultrasonography is so widely used by practitioners, internists and nephrologists in our catchment area, it is highly likely that the data for the 50-59 age group, where maximal penetrance is achieved, represent the prevalence data very close to the truth. Thus, we can state that ADPKD prevalence is up to 5-fold over-estimated. The consequence of this re-definition softens the relevance of research projects but provides a realistic foundation for upcoming projects. It also provides data for all stages of chronic progressive hereditary diseases: the most recent studies did not focus on all ADPKD patients, but only on those with mild to moderately impaired renal function (Stage 2) which accounts only for about 25% of all ADPKD patients.
In conclusion, we provide an unbiased, fully ascertained, population-based prevalence estimate for ADPKD which is lower than what most nephrologists and geneticists are aware of.
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